The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I feel Valirx is being judged on past performance by many.
If the company were a new entity there would be a great deal of excitement created from the recent announcement.
In some respects Valirx could be viewed as a new entity, indeed with 3 new additions to the board and recruiting for a new CEO the board structure has been transformed.
Couple that with the progress made recently.
*Ongoing evaluation projects.
*INAPHAEA
Setting up the lab to the make progress of evaluation projects both more cost effective and creating an environment for development.
Being on the verge of commerciality after a period of developing its services.
*Two clinical stage assets.
*CLX001. Showing great promise, recently receiving a grant from the OP with its lead formulation currently going through safety tests.
I am clearly a shareholder and for many reasons want the company to do well.
There will be people with a legitimate opposing view and some with an agenda who will do and say anything to discredit the company but I remain very optimistic for the future of Valirx.
Thank f**k the market is shut on Monday. 😉
So we get a RNS earlier in the week which gave the acolytes and optimists a semi. Great things promised and even the major shareholder excitedly took to Twitter or Twatter whatever it's called these days.
I now note that the mid close last Friday was 2.20p and today it's 2.88p.
I think the market probably reflects the factual assessments made by Porky and sees very little to get excited about.
Ah ok.....
Porky you have experience of that no doubt with 4D dropping from 90p down to 0p and the largest holder was smacking it whilst you were printing your buys on Twitter. It shows the difference between a pro and an amateur who can read a basic financial report.
The last person I would listen to is Porky. Buy low and sell high and with cash well into 2025 it should just be up from here with news to come and not really priced in.
@Uncanny
LMOL - You don't have a clue, you have no idea of my investment profile, further its none of your business either so you can think and make up what you like. It wont change the position here.
Just recently ,you were played yet again like a Stradivarius, in came the ramping crew at 1.8p ramped it, feed some BS, company put out some spin, share price spiked at 3.7p and those that were ahead of the game cashed IN taking a very nice profit with them whilst the suckers were left holding the baby wondering what's hit them as the SP drifts back to 1.8p again.
Same old same old....
Hopist
They were allowing buys under the mid, hence the drop later on, a dummy buy showed it this morning.
I wouldn't be sorry for him. He wants everyone to end up potless like himself. Not invested in any share whatsoever, but spends all day on a BB warning people about how bad the current b.o.d. are. Weirdo.
Don't think so Seancadman, mid price was 3.05 on Open....
Sour grapes Porky, sorry for your losses mate.
I would think we will have lots of hype multiple times in the next 9-12 months before cash runs out but hopefully a deal will extend that much further.
CLX- 20 million upfront payment plus 800 million milestones by AZ. If we wake up to that one day it would be the greatest day in AIM history. Hopefully they will make it happen. CLX will not be difficult to get partnered with.
Just 142000 shares traded by 1pm. Just shows what a totally manufacturered spike
this was by those in the know..
As for quoting people's quotes from nearly 3 years ago, you're just shooting yourselves in the foot by quoting the 50p plus price it was trading at on complete hype. Not only has nothing come to fruition since then but it would tell any potential punter to steer well clear.
The next placing will be lower than the last one.
The first 5 trades are actually buys, trading is pretty even so far.
Strong on the Ask ( 3 v 1) and only sells today so far....
GLA
@PM2022
What’s the point of quoting me from Oct 21 ie before they gave away what was our top asset to a potless start up. Back then there were dreams of multi million deals, just like you are still peddling today but reality is that the market changed. The landscape is now totally different.
The business couldn’t get a deal with a major that had cash hence why they offered it to a start up. 3 yrs later that start up still can’t get funded that’s the reality.
Porky9
Posted in: VAL
Posts: 6,926
Price: 52.50
Strong Buy
Burying Some Myths25 Oct 2021 21:16
1. I have a vested interest in the business doing well. I am a shareholder; I’m adding to my position, and I have total confidence in the business delivering as outlined. I am not at T1 level but getting there.
2. Before I arrived at this forum this was possibly one of the most negative forums on LSE with historic shareholders doing nothing but moan 24/7 it was a god dam awful place to visit. It was certainly not a place to visit if you want to find out about the business. In fact, you were actively put off from investing Imo.
3. I have gone out on a limb to make as much noise as possible to bring attention to this business and attract new investors and I will continue to do so. I have continually kept reposting links and information in the hope that someone new visiting will pick it up and go onto researching the opportunity and hopefully join us.
4. The majority of the LTH could not even be bothered to ask questions of the new management team when they had the opportunity to do so. Why do I know this? Put simply I know who the bulk of the questions were raised by from conversations with fellow investors and frankly some LTH were so dam negative they couldn’t see any return here and simply didn’t bother.
5. Sentiment is finally changing, thank God, new investors are backing the business, the business is finally re-rating and the market cap of the business improving but it still has along way to go.
6. I have continually said that I believe fair value pre contracts is at the peer average 80p line 52m mcap and that I expect this to trade in the 74p to 85p until news breaks. On contract confirmation we will be well north of £65m mcap value £1 SP heading towards £130m mcap value £2 SP. That is my call. It has not changed since the start.
Now some here may not like my ultra bullish stance, I get that, but how can anyone somehow think that its in anyway acceptable for ells-13 to post here all weekend 22 posts on Sunday and today telling everyone to sell so that can try and get back in a few pence cheaper a good thing? It is not, it is damaging to this business. Further it is distracting for new investors visiting here who want to discover more.
Now unless you are shorting yourself or have sold out and want to get in cheaper, for the vast majority here that are long we want the company to continue its success and its share price to continue improving. This is my point. Why not shout about it, we have a lot of positivity here. All shareholders should get behind this great business.
Finally, FAO of jenny as its out of trading hours I will repost the Valirx song posted just for you to prove I do have a sense of humour however, come trading hours its business as usual.
Let us see this business and its share price airborne at a decent level and once that snowball is rolling it will continue. I genuinely want t
@Goomer
I don’t control the Share Price, if the business delivered its results showing it had actually delivered something, rather than just confirming increased spending and a need for yet another placing the position would be different.
@PM2022
Here you go again, x should be worth 20million, y should be worth 10m, it’s total Mickey Mouse, an asset is only worth what someone will pay for it. The lab for example has delivered £9k of revenue for a 3mth contract and it will need yet more cash chucked at it - it’s a financial liability. CLX which is potentially their best asset also needs a further 400k of work on it and at least 12 to 18mths off being positioned for anything, it needs cash it it’s long off generating any. There is nothing short term that will bring a meaningful amount of cash into this business and you know that.
Adrian needs to get cash burn back to a more manageable level and the new CEO will need at least a 12 mph cash runway ahead of them, where do you think that cash will come from? Question is if the BOD situation is not sorted out, I’m not sure Adrian will get placing 16 away even at discount. Who in their right mind would chuck more cash at this for more of the same?
Also 11 clients for the lab at an advanced stage. So clearly work is being done just means more upside if it is not priced in at the moment.
I haven’t been ramping pigman just showing new investors the real you and pointing out your agenda to push this down as much as you can . I don’t intend to attempt to discuss anything with you as like you said yourself “someone so sad and desperate that they want to see the low markrt cap value of a biotech involved in life changing cancer treatments reduce even further. just a total scum bag as far as i'm concerned.”
To be fair they have built the company well even though it is not reflected in the SP yet.
They got CLX, progressed it to a decent level, got Imperial and the staff that were able to get that compounds, Lab to help develop the compounds, other evaluation projects, implemented a great strategy and best of all a biotec that only burns less than 2 million but despite that has so much R and D going on which should reflect in our market cap soon.
It would be unprecedented if they now get a huge deal for CLX with maybe 20 million upfront payments and huge milestones. We would be a market cap of 50/100/150 burning less than 2 million.
@Goomer
No this is your ramping agenda to try to discredit posters rather than discuss the real issues of this penny share play. This is a business, it’s not some charity doing good, the directors have bled investors dry to feed their own pockets but you selectively try to push all that under the carpet like it’s never happened. It’s a lifestyle business.
Further they awarded themselves bonus payments when a) the company was on the verge of running out of cash and b) was trying to get cash in from placing number 15.
Also, The situation with THX for example has been not just badly handled but illustrates a complete lack of commercial acumen by the BOD. At the moment Adrian is trying to find a new CEO and BOD changes need to be made and I await the outcome of that.
So don’t come the self righteous cr@p with me, Shareholders have been treated with utter contempt by the BOD and anyone new to this penny play should be aware of that.
porky you have never wanted an informed discussion. in your eyes it’s “porkys right everyone else is wrong.” that’s now when your not invested and are trying to push the price down and that was also the case when you was holding stock and ramping it to the moon. have you forgotten already the way you used to **** off derampers and i quote yourself “ someone so sad and desperate that they want to see the low markrt cap value of a biotech involved in life changing cancer treatments reduce even further. just a total scum bag as far as i'm concerned.”
so shut up and crawl back into your hole. nobody wants to listen to your ramblings.
@OB
Problem is that the stock can’t be evaluated here whilst the two main ramping forum controllers keep deleting posts containing key aspects that would be potentially material for an informed decision. Basically if they don’t like it, it doesn’t fit the ramping agenda it gets removed. Hence why 7 posts this morning but only 4 showing.
During early stage preclinical testing:
CLX001 is a peptide that is intended to be delivered in a nanoformulation. While the nanoformulation is undergoing further optimisation, the unformulated peptide continues to undergo biological testing. Safety screen data generated in Q1 2023 confirms no immediate toxicology concerns. Regulatory planning activities have also been commenced.
Also peptides in general are very safe when used as drugs because they have very few side effects. Further information is on the website.
The biggest concern for CLX was getting the formulation right which is often difficult and based on a previous RNS it was a concern. I am personally not concerned about the safety aspect but obviously further testing is needed but if that passes the value would increase significantly. Don't forget the likes of SAR got to 200/300 million at one stage based on a preclinical drug so I think the upside is decent but it will depend if they need an early deal or to carry on.
https://www.valirx.com/cytolytix-limited
Nor is the 'formulation right' or is there 'Cash until H2 2025 without lab revenue'.
With 7 recommendations so far to PM's comment it suggests to me that a new cohort of investors have arrived, drawn in by the spike a few days ago. The BOD will be delighted to have them onboard as they will be adding to the pool of investors who might be happy to average down if they need to shift 2nd hand shares again.
There may even be enough new interest to facilitate a convertible loan deal.